Vasily Fedorin

Chief Operating Officer at

4BIO Ventures Management Ltd.

Distribution Services

Consumer Services

Finance

Profile

Vasily Fedorin is currently the Chief Operating Officer at 4BIO Ventures Management Ltd. He previously worked as a Marketing Manager at MS WESTFALIA GmbH from 2009 to 2010.
Dr. Fedorin holds a doctorate degree from Lomonosov Moscow State University Business School, which was conferred in 2008.

Vasily Fedorin active positions

Companies	Position	Start
4BIO Ventures Management Ltd. 4BIO Ventures Management Ltd. Investment ManagersFinance 4bio Ventures invest in companies located in the United Kingdom. The firm targets the companies operating in the fields of gene therapy, cell theray, RNA based therapy, targeted therapies and microbiome. They provide financing for early stage capital requirements.	Chief Operating Officer	2022-02-28

All active positions of Vasily Fedorin

Former positions of Vasily Fedorin

Companies	Position	End
MS WESTFALIA GmbH MS WESTFALIA GmbH Medical DistributorsDistribution Services Distributes medical equipment	Private Equity Investor	2010-01-31

See the detail of Vasily Fedorin's experience

Training of Vasily Fedorin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Vasily Fedorin's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	3
MS WESTFALIA GmbH MS WESTFALIA GmbH Medical DistributorsDistribution Services Distributes medical equipment	Distribution Services
Lomonosov Moscow State University Business School Lomonosov Moscow State University Business School Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
4BIO Ventures Management Ltd. 4BIO Ventures Management Ltd. Investment ManagersFinance 4bio Ventures invest in companies located in the United Kingdom. The firm targets the companies operating in the fields of gene therapy, cell theray, RNA based therapy, targeted therapies and microbiome. They provide financing for early stage capital requirements.	Finance